Dr. Lance Willsey was appointed Chairman of the Board on September 30, 2024. He was appointed member of the Board of Directors in December 2023. Dr. Lance Willsey, M.S., M.D. is a urologist who has an aggregate of 36 years of private and public board experience focused in the area of cancer diagnostics and therapeutics. He completed his surgical and urology training at the Massachusetts General Hospital and additional postgraduate training in the Steele Lab Harvard University and the Dana Farber Cancer Institute. Lance is a founding Partner of Healthcare fund DCF Capital. He also actively participated in boards as a Director of Exact Sciences from 1999 to 2009 and of Exelixis from 1997 to 2023. Lance helped guide the two companies through their IPO process as well as subsequent financings. He also has extensive experience in corporate governance having served on audit, compensation, finance and scientific advisory committees.